Population Pharmacokinetic Estimation Methods

Pharmacometrics: The Science of Quantitative Pharmacology

Volumn , Issue , 2006, Pages 263-285

  Ette, Ene I ^a,b   Williams, Paul J ^b,c   Ahmad, Alaa ^a  

^a VERTEX PHARMACEUTICALS   (United States)

^b Massachusetts   (United States)

^c UNIVERSITY OF THE PACIFIC   (United States)

Author keywords

Alternative first order; Alternative first order (MIXNLIN); Bayesian methods; Bayesian two stage approach; Conditional first order method (NLME); First order methods; First order conditional estimation (FOCE); Gibbs sampling; Global two stage (GTS) method; Individual model; Maximum likelihood; Na ve average data approach; Naive pooled data analysis; Nonlinear mixed effects model; NONMEM; Nonparametric expectation maximization (NPEM); Nonparametric maximum likelihood (NPML); Population model; Population pharmacokinetics; Random effects; Semi nonparametric maximum likelihood (SNP); Standard two stage (STS) approach; The iterative two stage (IT2S) approach; The two stage approach; Variability

Indexed keywords

EID: 84879406621     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470087978.ch10     Document Type: Chapter

References (81)

1. Guidance for Industry: Population Pharmacokinetics. U.S. Department of Health and Human Services, Food and Drug Administration, Washington, DC, 1999.
2. E. I. Ette and P. J. Williams, Population pharmacokinetics 1: background, concepts and models. Ann Pharmacother 38:1702-1706 (2004).
3. E. Chatelut, A. V. Boody, B. Peng, et al., Population pharmacokinetics of carboplatin in children. Clin Pharmacol Ther 59:436-443 (1996).
4. L. Collart, T. H. Blaschke, F. Bouch, et al., Potential of population pharmacokinetics to reduce the frequency of blood required for estimating kinetic parameters in neonates. Dev Pharmacol Ther 18 (1-2):71-80 (1992).
5. E. Yukawa, H. Mine, S. Higuchi, et al., Digoxin population pharmacokinetics from routine clinical data: role of patient characteristics for estimating dosing regimens. J Pharm Pharmacol 44:761-765 (1992).
6. P. Crome and R. J. Flanagan, Pharmacokinetic studies in elderly people: are they necessary? Clin Pharmacokinet 26(4):243-247 (1994).
7. S. M. Pai, U. A. Shukla, T. H. Grasela, et al., Population pharmacokinetic analysis of didadosine (2',3'-dideoxyinosine) plasma concentration obtained in phase I clinical trials in patients with AIDS or AIDS-related complex. J Clin Pharmacol Ther 32:164-169 (1995).
8. L. B. Sheiner and S. L. Beal, Evaluation of methods for estimating population pharmacokinetic parameters. I. Michealis-Menten model: routine clinical data. J Pharmacokinet Biopharm 8:553-571 (1980).
9. L. B. Sheiner and S. L. Beal, Evaluation of methods for estimating population pharmacokinetic parameters. I. Biexponential model and experimental pharmacokinetic data. J Pharmacokinet Biopharm 9:635-651 (1981).
10. L. B. Sheiner and S. L. Beal, Evaluation of methods for estimating population pharmacokinetic parameters. I. Monoexponential model and routine clinical data. J Pharmacokinet Biopharm 11:303-319 (1983).
11. E. Samara and R. Granne, Role of pharmacokinetics in drug development: a pharmaceutical industry perspective. Clin Pharmacokinet 32(4):294-312 (1997).
12. B. Whiting, A. W. Kelman, and J. Grevel, Population pharmacokinetics: theory and clinical application. Clin Pharmacokinet 11:387-401 (1986).
13. M. O. Karlsson and L. B. Sheiner, The importance of modeling interoccasion variability in population pharmacokinetic analyses. J Pharmacokinet Biopharm 21(6):735-750 (1993).
14. E. I. Ette and P. J. Williams, Population pharmacokinetics. II: Estimation methods. Ann Pharmacother 38:1907-1915 (2004).
15. M. O. Karlsson, S. L. Beal, and L. B. Sheiner, Three new residual error models for population PK/PD analyses. J Pharmacokinet Biopharm 23(6):651-672 (1995).
16. G. Levy and L. E. Hollister, Inter-and intrasubject variations in drug absorption kinetics. J Pharm Sci 53:1446-1452 (1964).
17. E. Martin, W. Moll, P. Schmid, and L. Dettli, Problems and pitfalls in estimating average pharmacokinetic parameters. Eur J Clin Pharmacol 26:595-602 (1984).
18. D. M. Cochetto, W. A. Wargin, and J. W. Crow, Pitfalls and valid approaches to pharmacokinetic analysis of mean concentration data following intravenous administration. J Pharmacokinet Biopharm 8:539-552 (1980).
19. L. B. Sheiner and S. L. Beal, Evaluation of methods for estimating population pharmacokinetic parameters. I. Michealis-Menten model: routine clinical data. J Pharmacokinet Biopharm 8:553-571 (1980).
20. L. B. Sheiner and S. L. Beal, Evaluation of methods for estimating population pharmacokinetic parameters. I. Biexponential model and experimental pharmacokinetic data. J Pharmacokinet Biopharm 9:635-651 (1981).
21. L. B. Sheiner and S. L. Beal, Evaluation of methods for estimating population pharmacokinetic parameters. I. Monoexponential model and routine clinical data. J Pharmacokinet Biopharm 11:303-319 (1983).
22. L. B. Sheiner and S. L. Beal, Estimation of pooled pharmacokinetic parameters describing populations, in Kinetic Data Analysis, L. Endrenyi (Ed.). Plenum Press, New York, 1981, pp. 271-284.
23. H. Fluehler, H. Huber, E. Widmer, and S. Brechbuehler, Experiences in the application of NONMEM to pharmacokinetic data analysis. Drug Metab Rev 15:317-339 (1984).
24. J. B. Dyck, D. L. Haack, L. Azarnoff, L. Vuorilehto, and S. L. Shafer, Computercontrolled infusion of intravenous dexmedetomide hydrochloride in adult human volunteers. Anesthesiology 78:821-828 (1993).
25. S. L. Shafer, J. R. Varvel, N. Aziz, and J. C. Scott, Pharmacokinetics of fentanyl administered by computer-controlled infusion pump. Anesthesiology 73:1091-1102 (1990).
26. L. L. Gustafsson, W. F. Ebling, E. Osaki, S. Harapat, D. R. Stanski, and S. L. Shafer, Plasma concentration clamping in the rat using a computer-controlled infusion pump. Pharm Res 9:800-807 (1992).
27. B. K. Kataria, S. A. Ved, H. F. Nicodemus, D. Lea, M. Y. Dubios, J. W. Mandema, and S. L. Shafer, The pharmacokinetics of propofol in children using three different data analysis approaches. Anesthesiology 80:104-122 (1994).
28. T. D. Egan, H. J. Lemmens, P. Fiset, D. J. Hermann, K. T. Muir, D. R. Stanski, and S. L. Shafer, The pharmacokinetics of the new short-acting opioid remifentanil (GI87084B) in healthy adult male volunteers. Anesthesiology 79:881-892 (1993).
29. B. E. Rodda, Analysis of sets of estimates from pharmacokinetic studies, in Kinetic Data Analysis, L. Endrenyi (Ed.). Plenum Press, New York, 1981, pp. 285-297.
30. J. L. Steimer, A. Mallet, J. L. Golmard, and J. F. Boisvieux, Alternative approaches to estimation of population pharmacokinetic parameters: comparison with nonlinear mixed effects model. Drug Metab Rev 15:265-292 (1984).
31. L. B. Sheiner and S. L. Beal, A note on confidence intervals with extended least squares parameter estimates. J Pharmacokinet Biopharm 15:93-98 (1987).
32. D. B. White, C. A. Walawander, Y. Tung, and T. H. Grasela, An evaluation of point and interval estimates in population pharmacokinetics using NONMEM analysis. J Pharmacokinet Biopharm 19:87-112 (1991).
33. G. Prevost, Estimation of a normal probability density function from samples measured with non-negligible and non-constant dispersion. Internal Report 6-77, Adersa-Gerbios, 2 avenue du 1er mai, F-91120 Palaiseau.
34. A. Forrest, C. H. Ballow, D. E. Nix, M. C. Birmingham, and J. J. Schentag, Development of a population pharmacokinetic model and optimal sampling strategy for intravenous ciprofloxacin in seriously ill patients. Antimicrob Agents Chemother 37:1065-1072 (1993).
35. R. W. Jellife, A. Schumitzky, and M. Van Guillder, User Manual for the Non-parametrric EM Program for Population Modeling, Version 2.17. Laboratory for Applied Pharmacokinetics, USC School of Medicine, Los Angeles, CA, 1993.
36. F. Mentre and R. Geomeni, A two-step iterative algorithm for estimation in nonlinear mixed-effect models with an evaluation in population pharmacokinetics. J Biopharm Stat; 5:141-158 (1995).
37. P-PHARM User's Guide, Version 1.3. SIMED, Créteil, France, 1994.
38. A. Racine-Poon, A Bayesian approach to nonlinear random effects models. Biometrics 41:1015-1023 (1985).
39. A. P. Dempster, N. M. Laird, and D. B. Rubin, Maximum likelihood from incomplete data via EM algorithm. J R Stat Soc B 39:1-38 (1977).
40. A. Racine, A. P. Grieve, H. Fluhler, and A. F. M. Smith, Bayesian methods in practice:experiments in the pharmaceutical industry. Appl Stat 35:93-100 (1986).
41. D. J. Spiegelhalter, A. Thomas, and W. Gilks, BUGS Manual 0.60. MRC Biostatistics Unit, Cambridge, UK, 1997.
42. N. G. Best, K. K. Tan, W. R. Gilks, and D. J. Spiegelhalter, Estimation of population pharmacokinetics using the Gibbs sampler. J Pharmacokinet Biopharm 23(4): 407-435 (1995).
43. D. J. Lunn, N. Best, A. Thomas, J. Wakefield, and D. J. Spiegelhalter, Bayesian analysis of population PK/PD models: general concepts and software. J Pharmacokinet Pharmacodyn 29(3):271-307 (2002).
44. L. B. Sheiner, B. Rosenberg, and K. L. Melmon, Modeling of individual pharmacokinetics for computer-aided drug dosage. Comp Biomed Res 5:441-459 (1972).
45. L. B. Sheiner, The population approach to pharmacokinetic data analysis: rationale and standard data analysis methods. Drug Metab Rev 15:153-171 (1984).
46. S. L. Beal, Population pharmacokinetic data and parameter estimation based on their first two statistical moments. Drug Metab Rev 15:173-193 (1984).
47. B. Whiting, A. W. Kelman, and J. Grevel, Population pharmacokinetics: theory and clinical application. Clin Pharmacokinet 11:387-401 (1986).
48. L. B. Sheiner and S. L. Beal, Bayesian individualization of pharmacokinetics: simple implementation and comparison with non-Bayesian methods. J Pharm Sci 71:1344-1348 (1982).
49. E. I. Ette, A. W. Kelman, C. A. Howie, and B. Whiting, Analysis of animal pharmacokinetic data: performance of the one point per animal design. J Pharmacokinet Biopharm 23:551-566 (1995).
50. E. I. Ette, H. Sun, and T. M. Ludden, Balanced designs and longitudinal population pharmacokinetic studies. J Clin Pharmacol 38:417-423 (1998).
51. T. H. Grasela, Jr., E. J. Antal, R. J. Townsend, and R. B. Smith, An evaluation of population pharmacokinetics in therapeutic trials. Part I. Comparison of methodologies. Clin Pharmacol Ther 39:605-612 (1986).
52. L. Collart, T. F. Blashke, F. Boucher, and C. G. Prober, Potential of population pharmacokinetics to reduce the frequency of blood sampling required for estimating kinetic parameters in neonates. Dev Pharmacol Ther 18:71-80 (1992).
53. L. Aarons, J. W. Mandema, and M. Danhof, A population analysis of the pharmacokinetics and pharmacodynamics of midazolam in the rat. J Pharmacokinet Biopharm 19:485-496 (1991).
54. N. Kaniwa, N. Aoyagi, H. Ogata, and M. Ishi, Application of the NONMEM method to evaluation of the bioavailability of drug products. J Pharm Sci 79:1116-1120 (1990).
55. S. M. Pai, U. A. Shukla, T. H. Grasela, et al., Population pharmacokinetic analysis of didanosine (2',3'-dideoxyinosine) plasma concentration obtained in phase I clinical trials in patients with AIDS or AIDS-related complex. J Clin Pharmacol 32:242-247 (1992).
56. C. D. Jones, H. Sun, and E. I. Ette, Designing cross-sectional population pharmacokinetic studies: implications for pediatric and animal studies. Clinc Res Regul Affairs 13:133-165 (1996).
57. A. Racine, A. P. Grieve, H. Fluhler, and A. F. M. Smith, Bayesian methods in practice:experiences in pharmaceutical industry. Appl Stat 35:1-38 (1986).
58. E. I. Ette, A. W. Kelman, C. A. Howie, and B. Whiting, Influence of interanimal variability on the estimation of population pharmacokinetic parameters in preclinical studies. Clin Res Reg Affairs 11:121-139 (1994).
59. E. I. Ette, C. A. Howie, A. W. Kelman, and B. Whiting, Experimental design and effi-cient parameter estimation in preclinical pharmacokinetic studies. Pharm Res 12:729-737 (1995).
60. M. O. Karlsson and L. B. Sheiner, The importance of modeling interoccasion variability in population pharmacokinetic analyses. J Pharmacokinet Biopharm 21(6):735-750 (1993).
61. S. L. Beal and L. B. Sheiner, NONMEM Users Guide-Part VII. Conditional estimation Methods. University of California, San Francisco, 1992.
62. M. J. Lindstrom and D. M. Bates, Nonlinear mixed effects models for repeated measures data. Biometrics 46:673-687 (1990).
63. S-Plus TM. Insightful, Seattle, Washington, 2002.
64. E. F. Vonesh and R. L. Carter, Mixed-effects nonlinear regression for unbalanced repeated measures. Biometrics 46:673-687 (1992).
65. E. F. Vonesh, Nonlinear models for the analysis of longitudinal data. Stat Med 11:1929-1954 (1992).
66. R. D. Wolfinger, Laplace's approximation for nonlinear mixed models. Biometrika 80:791-795 (1993).
67. A. Mallet, A maximum likelihood estimation method for random coefficient regression models. Biometrika 73:645-656 (1986).
68. J. L. Steimer, A. Mallet, and F. Mentre, Estimating interindividual pharmacokinetic variability, in Variability in Drug Therapy: Description, Estimation, and Control, M. Rowland et al. (Eds.). Raven Press, New York, 1985, pp. 65-111.
69. F. Mentre and A. Mallet, Experiences with NPML-application to dosage individualisation of cyclosporine, gentamicin and zidovudine, in The Population Approach, M. Rowland and L. Aarons (Eds.). Commission of European Communities, Luxembourg, 1992, pp. 75-90.
70. A. Mallet, F. Mentre, J. Gilles, A. W. Kelman, A. N. Thomson, S. M. Bryson, and B. Whiting, Handling covariates in population pharmacokinetics with an application to gentamicin. Biomed Meas Inform Contr 2:673-683 (1988).
71. A. Mallet, F. Mentre, J. L. Steimer, and F. Lokiec, Nonparametric maximum likelihood estimation for population pharmacokinetics, with application to cyclosporine. J Pharmacokinet Biopharm 16:529-556 (1988).
72. F. Mentre, A. Mallet, B. Diquet, et al., Population kinetics of AZT in AIDS patients. Eur J Clin Pharmacol 36:230 (1989).
73. J. S. Sidhu, M. Ashton, N. V. Huong, et al., Artemisinin population pharmacokinetics in children and adults with uncomplicated falciparum malaria. Br J Clin Pharmacol 45:347-354 (1998).
74. M. Hossain, E. Wright, R. Baweja, T. M. Ludden, and R. Miller, Nonlimear mixed effects modeling of single dose and multiple dose data for an immediate release (IR) and controlled release (CR) dosage form of alprazolam. Pharm Res 14:309-315 (1997).
75. A. Schumitzky, Nonparametric EM algorithms for estimating prior distributions. Appl Math Comput 45:141-157 (1991).
76. W. F. Dodge, R. W. Jellife, C. J. Richardson, R. A. McCleery, J. A. Hokanson, and W. R. Snodgrass, Gentamicin population pharmacokinetic models for low birth weight infants using a new nonparamaetric method. Clin Pharmacol Ther 50:25-31 (1991).
77. R. W. Jellife, P. Gomis, and A. Schumitzky, A population model of gentamicin made with a new nonparametric EM algorithm. Technical Report 90-4. Laboratory for Applied Pharmcokinetics, USC School of Medicine, Los Angeles, CA, 1990.
78. M. Davidian and A. R. Gallant, Smooth nonparametric maximum likelihood estimation for population pharmacokinetcs, with application to quinidine. J Pharmacokinet Biopharm 20:529-556 (1992).
79. M. Davidian and A. R. Gallant, The nonlinear mixed effects model with a smooth random effects density. Institute of Statistics Mimeo Series No. 2206, North Carolina State University, Raleigh, NC, 1992.
80. A. R. Gallant and D. W. Nychka, Semi-nonparametric maximum likelihood estimation. Econometrica 55:363-390 (1987).
81. K. E. Fattinger, L. B. Sheiner, and D. Verotta, A new method to explore the distribution of interindividual random effects in nonlinear mixed effects models. Biometrics 51:1236-1251 (1995).